Advertisement
UK markets closed

  • FTSE 100

    7,554.47
    +40.75 (+0.54%)
     

  • FTSE 250

    18,701.99
    +83.25 (+0.45%)
     

  • AIM

    723.45
    +2.59 (+0.36%)
     

  • GBP/EUR

    1.1653
    -0.0005 (-0.04%)
     

  • GBP/USD

    1.2551
    -0.0043 (-0.34%)
     

  • Bitcoin GBP

    35,173.62
    +711.18 (+2.06%)
     

  • CMC Crypto 200

    914.81
    +18.10 (+2.02%)
     

  • S&P 500

    4,604.37
    +18.78 (+0.41%)
     

  • DOW

    36,247.87
    +130.49 (+0.36%)
     

  • CRUDE OIL

    71.26
    +1.92 (+2.77%)
     

  • GOLD FUTURES

    2,020.80
    -25.60 (-1.25%)
     

  • NIKKEI 225

    32,307.86
    -550.45 (-1.68%)
     

  • HANG SENG

    16,334.37
    -11.52 (-0.07%)
     

  • DAX

    16,759.22
    +130.23 (+0.78%)
     

  • CAC 40

    7,526.55
    +98.03 (+1.32%)
     
property:

10 former rectories and vicarages for sale

Many are spacious and full of character and charm

Why CureVac Stock Plunged Today

Steve Symington, The Motley Fool
·2-min read
Why CureVac Stock Plunged Today

Shares of CureVac (NASDAQ: CVAC) were down 9.1% as of 2:45 p.m. ET Thursday after a German court temporarily suspended the biopharmaceutical company's patent trial against BioNTech (NASDAQ: BNTX). CureVac previously failed to develop a successful COVID-19 vaccine during the pandemic, opting instead to focus on potential second-generation vaccines in partnership with GlaxoSmithKline. BioNTech, by contrast, generated tens of billions of dollars in annual revenue from its successful mRNA vaccines developed in partnership with Pfizer.

Continue reading